MX2022013692A - Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. - Google Patents
Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo.Info
- Publication number
- MX2022013692A MX2022013692A MX2022013692A MX2022013692A MX2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A
- Authority
- MX
- Mexico
- Prior art keywords
- kdm5
- azabicyclo
- inhibitory activity
- hexane derivatives
- disease
- Prior art date
Links
- 150000005228 3‐azabicyclo[3.1.0]hexanes Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020088925 | 2020-05-07 | ||
| PCT/CN2021/091843 WO2021223699A1 (en) | 2020-05-07 | 2021-05-06 | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013692A true MX2022013692A (es) | 2022-11-30 |
Family
ID=76159223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013692A MX2022013692A (es) | 2020-05-07 | 2021-05-06 | Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11691968B2 (https=) |
| EP (2) | EP4471027A1 (https=) |
| JP (3) | JP7643466B2 (https=) |
| KR (2) | KR20260046494A (https=) |
| CN (1) | CN115461338B (https=) |
| AU (1) | AU2021268223B2 (https=) |
| BR (1) | BR112022022005A2 (https=) |
| CA (1) | CA3181604A1 (https=) |
| ES (1) | ES3037418T3 (https=) |
| IL (1) | IL297900B2 (https=) |
| MX (1) | MX2022013692A (https=) |
| NZ (1) | NZ793960A (https=) |
| TW (1) | TWI895412B (https=) |
| WO (1) | WO2021223699A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3999183A4 (en) * | 2019-07-17 | 2023-11-15 | Ono Pharmaceutical Co., Ltd. | COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES |
| ES3037418T3 (en) | 2020-05-07 | 2025-10-01 | Ono Pharmaceutical Co | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物 |
| WO2025239445A1 (ja) * | 2024-05-17 | 2025-11-20 | 小野薬品工業株式会社 | 認知症の行動および心理症状の予防、進行抑制および／または治療剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI244481B (en) * | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB0311859D0 (en) | 2003-05-22 | 2003-06-25 | Merck Sharp & Dohme | Therapeutic agents |
| JP5017103B2 (ja) | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 薬剤共結晶組成物および関連した使用方法 |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| RU2487127C2 (ru) | 2007-10-09 | 2013-07-10 | Ф.Хоффманн-Ля Рош Аг | Хиральные цис-имидазолины |
| CN107912040B (zh) * | 2014-10-10 | 2021-04-06 | 基因泰克公司 | 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物 |
| CN108341819B (zh) | 2017-01-22 | 2021-06-15 | 南京药捷安康生物科技有限公司 | 磷酸二酯酶抑制剂及其用途 |
| EP3999183A4 (en) | 2019-07-17 | 2023-11-15 | Ono Pharmaceutical Co., Ltd. | COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES |
| ES3037418T3 (en) | 2020-05-07 | 2025-10-01 | Ono Pharmaceutical Co | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
-
2021
- 2021-05-06 ES ES21728166T patent/ES3037418T3/es active Active
- 2021-05-06 MX MX2022013692A patent/MX2022013692A/es unknown
- 2021-05-06 KR KR1020267006670A patent/KR20260046494A/ko active Pending
- 2021-05-06 CA CA3181604A patent/CA3181604A1/en active Pending
- 2021-05-06 AU AU2021268223A patent/AU2021268223B2/en active Active
- 2021-05-06 CN CN202180032139.2A patent/CN115461338B/zh active Active
- 2021-05-06 NZ NZ793960A patent/NZ793960A/en unknown
- 2021-05-06 EP EP24182835.9A patent/EP4471027A1/en active Pending
- 2021-05-06 KR KR1020227037880A patent/KR102937044B1/ko active Active
- 2021-05-06 BR BR112022022005A patent/BR112022022005A2/pt unknown
- 2021-05-06 TW TW110116409A patent/TWI895412B/zh active
- 2021-05-06 WO PCT/CN2021/091843 patent/WO2021223699A1/en not_active Ceased
- 2021-05-06 EP EP21728166.6A patent/EP4146645B1/en active Active
- 2021-05-06 JP JP2022567355A patent/JP7643466B2/ja active Active
- 2021-05-06 IL IL297900A patent/IL297900B2/en unknown
-
2022
- 2022-10-24 US US17/971,844 patent/US11691968B2/en active Active
-
2023
- 2023-05-05 US US18/144,030 patent/US12269817B2/en active Active
-
2024
- 2024-10-02 JP JP2024173464A patent/JP7643632B2/ja active Active
-
2025
- 2025-02-26 JP JP2025029239A patent/JP2025081677A/ja not_active Withdrawn
- 2025-02-28 US US19/067,084 patent/US20250214984A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL297900B2 (en) | 2026-04-01 |
| JP7643466B2 (ja) | 2025-03-11 |
| WO2021223699A1 (en) | 2021-11-11 |
| JP2023524547A (ja) | 2023-06-12 |
| IL297900B1 (en) | 2025-12-01 |
| CN115461338A (zh) | 2022-12-09 |
| IL297900A (en) | 2023-01-01 |
| US12269817B2 (en) | 2025-04-08 |
| EP4146645A1 (en) | 2023-03-15 |
| US20230271952A1 (en) | 2023-08-31 |
| TWI895412B (zh) | 2025-09-01 |
| CA3181604A1 (en) | 2021-11-11 |
| KR20260046494A (ko) | 2026-04-07 |
| TW202200571A (zh) | 2022-01-01 |
| JP7643632B2 (ja) | 2025-03-11 |
| JP2025081677A (ja) | 2025-05-27 |
| KR20230007352A (ko) | 2023-01-12 |
| AU2021268223B2 (en) | 2025-10-09 |
| AU2021268223A1 (en) | 2022-12-08 |
| CN115461338B (zh) | 2024-02-20 |
| US20250214984A1 (en) | 2025-07-03 |
| EP4471027A1 (en) | 2024-12-04 |
| BR112022022005A2 (pt) | 2022-12-13 |
| US20230109293A1 (en) | 2023-04-06 |
| JP2024177345A (ja) | 2024-12-19 |
| KR102937044B1 (ko) | 2026-03-09 |
| ES3037418T3 (en) | 2025-10-01 |
| EP4146645B1 (en) | 2025-06-25 |
| US11691968B2 (en) | 2023-07-04 |
| NZ793960A (en) | 2025-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013692A (es) | Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. | |
| WO2020104648A3 (en) | TGFβ INHIBITOR AND PRODRUGS | |
| NZ539841A (en) | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | |
| PH12023550119A1 (en) | Egfr inhibitor | |
| GB0225475D0 (en) | Therapeutic agents | |
| ZA202204666B (en) | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors | |
| MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
| MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| NO20070606L (no) | Inhibitorer av IAP | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| GB0318447D0 (en) | Therapeutic agents | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| TN2020000125A1 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| ZA202100352B (en) | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | |
| MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| MX2020004588A (es) | Inhibidor de proteasa de doble cabeza. | |
| DE60232173D1 (de) | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme | |
| PT1606288E (pt) | Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor | |
| MX2022004912A (es) | Novedoso compuesto de anillo condensado sustituido. | |
| WO2006050861A3 (en) | Statine derivatives for the treatment of alzheimer's disease |